Bluemtec has made a strategic investment in Medistaff, a secure messaging platform for physicians, becoming the latter’s second-largest shareholder.

Bluemtec said Tuesday that it has recently acquired Medistaff's common stock, making it the company's second-largest shareholder. Bluemtec now owns 16.6 percent of the company. Bluemtec operates Blue Pharm Korea, a specialty drug platform for hospitals, and was listed on the tech-heavy Kosdaq market last December.

Medistaff has launched the MediStaff application, an exclusive messenger platform for physicians with over 40,000 members. Its main services include providing a community for information exchange among physicians, conducting surveys on healthcare business, and holding academic seminars for physicians.

Based on the strategic investment, the two companies plan to work together to find ways to enhance and synergize community services, according to Bluemtec.

"We will create a service model that can accompany doctors' lives based on a secure messenger platform exclusively for doctors," Medistaff CEO Kii Dong-hoon said. "We will create synergies in various forms with Bluemtec's hospital platform service."

"By connecting the services of Medistaff, whose major users are specialists and volunteer doctors, and Bluemtec, whose major customers are clinic owners, we can lay the foundation for providing platform services for medical staff of all ages," Bluemtec CEO Kim Hyun-soo said. "We expect the transfer of the stake in Medistaff will be an opportunity for both companies to grow."